Hence, in almost all cancers, in addition to the RB pathway the p53 pathway is also disabled by oncogenic changes including deletion or mutation of ARF or p53, or Hdm2 over-expression, which ubiquitinates p53 for proteasome-mediated degradation [20], enabling cancer cells to survive. This evidence concerns the gene CDKN2A and cancer.